Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection

A complete 2-drug regimen of dolutegravir at 50 mg and rilpivirine at 25 mg was approved to treat HIV-1 infection in virologically suppressed patients after demonstrating acceptable efficacy and tolerability. This study investigated the bioequivalence and pharmacokinetics of the fixed-dose combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rashmi, Wolstenholme, Allen, Di Lullo, Kristin, Fu, Caifeng, Joshi, Shashidhar, Crauwels, Herta, Givens, Naomi, Vanveggel, Simon, Wynne, Brian, Adkison, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125541/
https://www.ncbi.nlm.nih.gov/pubmed/29987139
http://dx.doi.org/10.1128/AAC.00748-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125541/
https://www.ncbi.nlm.nih.gov/pubmed/29987139
http://dx.doi.org/10.1128/AAC.00748-18

Ejemplares similares